FLORIDA SOCIETY OF CLINICAL ONCOLOGY

The Voice of Oncology in Florida

FLASCO FLASH | April 21, 2016

FLASCO WEBSITE: www.flasco.org

Click Here to Make a donation to the **FLASCO Foundation**

Message from the FLASCO President

Meetings with UHC and Florida Blue


Members of the FLASCO leadership team will be holding individual telephone conference calls with representatives from United Health Care and Florida Blue in early May.

If you have any questions, concerns or issues that you would to be considered for discussion on these calls please contact the FLASCO Executive Director by April 28, 2016. (Dorothy.green@flasco.org)

We Are Pleased To Announce the Newest 2016 FLASCO Corporate Members



bioTheranostics, Inc.



Thank you for supporting Your Florida Society of Clinical Oncology!

DRUG, DEVICE & INDUSTRY NEWS



FDA Approves Gilotrif® (Afatinib) As New Oral Treatment Option for Patients with Squamous Cell Carcinoma of the Lung

Boehringer Ingelheim announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Gilotrif® (afatinib) tablets for the treatment of patients with advanced squamous cell carcinoma of the lung whose disease has progressed after treatment with platinum-based chemotherapy. read article »

FDA Approves Defibrotide Sodium for the Treatment of Adult and Pediatric Patients with Hepatic Venoocclusive Disease


On March 30, 2016, the U. S. Food and Drug Administration <u>approved</u> Defitelio (defibrotide sodium, Jazz Pharmaceuticals, Inc.) for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstructive syndrome, with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT). <u>Read more</u>.

FDA Finds No Deficiency with Heron Therapeutics' Sustol NDA

The US Food and Drug Administration (FDA) has indicated that there are no substantive deficiencies in Heron Therapeutics' new drug application (NDA) for Sustol (granisetron) Injection (extended release) to treat acute and delayed chemotherapy-induced nausea and vomiting (CINV). read article »

Drug Shortages: CURRENT DRUG SHORTAGES AND DISCONTINUATIONS INDEX

FDA's Directory: NATIONAL DRUG CODE DIRECTORY



FDA Clarifies Compounding Rules

The <u>Food and Drug Administration</u> issued three draft guidance documents on Friday that answer providers' and pharmacists' burning questions about drug compounding standards.

The proposed rules clarify the amount of drugs that providers can compound without a prescription, set requirements for health system compounding pharmacies and clarify how large-scale compounding sites known as "outsourcing facilities" may be set up. This follows two reports from the Pew Charitable Trusts that found compounding oversight is largely left up to the states and varies widely. Read more

CMS Drops Two-Midnight Rule's Inpatient Payment Cuts

The CMS will not impose an inpatient payment cut to hospitals under the two-midnight rule following ongoing industry criticism and a legal challenge. Read More

Bendamustine hydrochloride (Treanda®) -- revision to the Part A and Part B LCD

LCD ID number: L33268 (Florida/Puerto Rico/U.S. Virgin Islands)

The local coverage determination (LCD) for Bendamustime hydrochloride (Treanda®) was revised based on a LCD reconsideration request to include BendekaTM which was approved by the Food and Drug Administration (FDA) on December 7, 2015. The title of the LCD and the "Indications and Limitations of Coverage and/or Medical Necessity" section of the LCD were revised to add BendekaTM. Also, Healthcare Common Procedure Coding System (HCPCS) codes C9399 and J9999 were added in the "CPT®/HCPCS Codes" section of the LCD. In addition, the "Sources of Information and Basis for Decision" section of the LCD was updated.

Effective date: This LCD revision is effective for claims processed on or after April 14, 2016, for services rendered on or after December 7, 2015. LCDs are available through the CMS Medicare coverage database at https://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx external.gif.



LEGISLATIVE UPDATE:

Michael Diaz, MD – Chairman Federal Craig Deligdish, MD – Chairman State William Harrer, MD – Co- Vice Chairman State Scott Tetreault, MD - Co-Vice Chairmen Federal & State

Florida Enacted State Laws Protecting Consumers Against Surprise Out-Of-Network Medical Bills

Florida last week <u>enacted one of the strongest state laws protecting consumers</u> against surprise out-of-network medical bills. What got less attention is that on the same day, <u>Republican Gov. Rick Scott also signed into law</u> what could turn out to be one of the nation's most robust healthcare price and quality transparency systems.

The law's sponsors apparently came up with a creative way around a <u>recent U.S. Supreme Court decision barring</u> states from requiring self-insured employers to share their cost data with state all-payer claims databases. That ruling poses a major hurdle to state transparency and cost-containment efforts. <u>Continue Reading</u>

Don't forget: Contact Congress and ask them to Stop the Cancer Experiment!

The next two weeks are critical to stopping the misguided Medicare experiment on cancer care! Make your voice heard - call, email, Tweet, and send Facebook messages to your elected officials asking them to Stop the Medicare Experiment on Cancer Care.

COA has set up the CancerExperiment.com website for easy advocacy action. Share the website with patients and advocates for them to get engaged directly, or download the advocacy toolkit to bring the effort into your practice. Check out www.CancerExperiment.com.



Mark Your Calendars!

Florida Hospital Cancer Institute Best of ASCO® will be held on June 18-19, 2016, at the Hyatt Regency Grand Cypress in Orlando. FLASCO is co-sponsoring this event. Click here to register



Welcome to FLASCO!

We hope you will find FLASCO

relevant to your career and that

you will be a long standing active

member for many years to come.

Memorial
Cancer Institute

Memorial Cancer Institute Best of ASCO® will be held on July 8th-10th, 2016, at the JW Marriott Marquis in Miami. FLASCO is co-sponsoring this event. A FLASCO & MCI session, dedicated to healthcare changes in the oncology practice, has been added for the 2016 event. Click here to view event.

Florida Pancreas Cancer Coalition Summit

FLASCO Member, Dr. Thomas George invites you to attend the Florida Pancreas Cancer Coalition Summit May 21, 2016 from 8:00am to 3:30pm in Orlando at the Renaissance Hotel at Sea World. FLASCO is cosponsoring this event. To register to attend, please visit http://www.flpcc.org/1067/Page.aspx





 \rightarrow

FLASCO MEMBERSHIP UPDATE:

Thomas George, MD - Chairman

Winston Tan, MD & Dina Dumercy, PharmD - Co-Vice Chairmen

NEW REGULAR MEMBER:

Rasha Beg, MD – Florida Cancer Specialists & Research Institute

NEW AFFILIATE MEMBERS:

Jeffrey "Alex" Bika, RPT—Health First Cancer Institute Erica Corcoran, RN—Florida Hospital Cancer Institute

Yamile Leon, RN, BSN, OCN, CN-BN - Miami Cancer Institute/Baptist Health South Florida

Jaime McCov, CPC, CHONC – Medical Associates of Brevard

Tricia Pecora. RN – Moffitt Cancer Center

Deborah Reagan – InterCommunity Cancer Center/Vantage Oncology

Lisa Shelar, RHIT – 21st Century Oncology

NEW COURTESY MEMBER:

Janine Fermanian, MS – Ipsen Biopharmaceuticals, Oncology/Hematology Sales Leader

Thank you to FLASCO's 100% Membership Partners



Broward Health Memorial Cancer Institute

Cancer Care Centers of Brevard Mid Florida Hematology and Oncology

Cleveland Clinic Florida Moffitt Cancer Center

Winter Haven Hospital Cassidy Cancer Center Oncology and Hematology Associates of West Broward

Florida Cancer Specialists

Oncology Resource Networks
Florida Hospital Gynecologic Oncology

Premier Hematology & Oncology

Mayo Clinic Florida

University of Florida

University of Florida Cancer Center – Orlando Health

Page **3** of **7**



National Association News

NCCN Holds Fifth Annual State Oncology Society Forum to Discuss Value in Cancer Care, Best **Practices**

The Florida Society of Clinical Oncology applauds and congratulates NCCN for providing its recent fifth annual NCCN State Oncology Society Forum which was held in conjunction with the NCCN 21st Annual Conference: Advancing the Standard of Cancer CareTM. A topic of focus at this year's Forum was how best to create and measure value in oncology care. With rising costs, the current healthcare climate is calling for indication of quality – validation that the most effective treatment is being utilized for people with cancer while, at the same time, mitigating escalating costs. The challenge stakeholders face today is how to reconcile the subjectivity involved while discussing value. Read More >

ASCO Adapts Cancer Care Ontario Guideline on Breast Cancer Treatments

ASCO has adapted the Cancer Care Ontario Guideline on adjuvant chemotherapy regimens for early breast cancer and adjuvant targeted therapy for HER2-positive breast cancers. Read the full guideline adaptation now.

New Certificate Program for Advanced Practice Providers Launched on ASCO University

Developed in partnership with professional societies that represent the full healthcare team, certificate programs for advanced practitioners who are joining oncology care settings are now available on ASCO University. These programs are designed to provide tailored education to providers with varying levels of experience, and all courses can be taken for CME, Nursing, and Pharmacy Credit. Register now

NCCN Pocket Guidelines for Multiple Myeloma, Non-Small Cell Lung Cancer, and Prostate Cancer **Available for FREE**

This printed version of the NCCN Guidelines is conveniently sized to fit in a lab coat pocket and serve as a valuable reference tool for physicians, nurses, pharmacists, and other oncology healthcare professionals. More >



Update ADMINISTRATIVE UPDATES:

Hospital Inpatient Prospective Payment System (IPPS) and Long - Term Acute Care Hospital (LTCH) Proposed Rule Issues for Fiscal Year (FY) 2017

On April 18, 2016, the Centers for Medicare & Medicaid Services (CMS) issued a proposed rule to update fiscal year (FY) 2017 Medicare payment policies and rates under the Inpatient Prospective Payment System (IPPS) and the Long-Term Care Hospital (LTCH) Prospective Payment System (PPS). The proposed rule, which would apply to approximately 3,330 acute care hospitals and approximately 430 LTCHs, would affect discharges occurring on or after October 1, 2016.

The IPPS pays hospitals for services provided to Medicare beneficiaries using a national base payment rate, adjusted for a number of factors that affect hospitals' costs, including the patient's condition and the cost of hospital labor in the hospital's geographic area. Read more

First Coast Service Options – Part A & B

> Hemophilia clotting factors -- revision to the Part A and Part B LCD

Modified: 4/14/2016Location: FL, PR, USVILine of Business: Part A, Part B

The MAC JN local coverage determination (LCD) for Hemophilia clotting factors was revised based on the Centers for Medicare & Medicaid Services (CMS) change request (CR) 9549.

> Medicare open public meeting schedule -- for draft local coverage determinations

Modified: 4/15/2016Location: PRLine of Business: Part A, Part B

Medicare open public meetings scheduled for 2016.

> Provider enrollment requirements for writing prescriptions for Medicare Part D

Modified: 4/20/2016Location: FL, PR, USVILine of Business: Part A, Part B


The Centers for Medicare & Medicaid Services (CMS) finalized new rules requiring physicians and professionals who write prescriptions for Part D drugs to be enrolled in an approved status or have a valid opt-out affidavit for their prescriptions to be covered by Medicare. This article was revised April 18 to show additional date changes related to the delayed enforcement of the Part D prescriber enrollment requirement until February 1, 2017. All other information remains the same. [SE1434]

MLN ConnectsTM Provider eNews April 21, 2016

View the MLN Connects™ Provider eNews View this edition as a PDF

JOB BOARD:

Administrative Director of Cancer Research at Florida Hospital Cancer Institute





Job Summary: In conjunction with the VP, oversees, directs, and creates best practices and execution of Cancer Institute clinical trials and translational clinical research through daily management of research staff. Ensures department compliance with various regulatory agencies, manages critical relationships with multiple teams, and guides the department toward continued excellence. The Director works closely with VP, Florida Hospital's senior executive and operations teams; Cancer Scientific Director and FHCI Administrator; as well as partners, organizations, external industry and academia; and local, state, and federal government to implement strategic partnerships as we continue to position and brand Florida Hospital as a preeminent and global pacesetter for clinical and translational cancer research. Actively participates in outstanding customer service and accepts responsibility in maintaining relationships that are equally respectful to all. Click here for more information

RN Position Available in Zephyrhills, FL

The Florida Medical Clinic, P.A. in Zephyrhills, FL is looking for an Oncology Registered Nurse

Job Summary: Provides specialized oncology nursing care to patients in an outpatient setting.

Job Qualifications:

- Current Active Florida RN license
- Current Chemotherapy Certification
- Prefer at least 1 year experience in oncology
- OCN preferred not required
- Current BLS
- ACLS preferred not required
- Strong customer service orientation
- Basic computer proficiency

Please forward resume to: jabrown@floridamedicalclinic.com

Please click here for more information

ADDITIONAL EDUCATIONAL OPPORTUNITIES

Oncology Nursing Certification Review Course

Save the Date! Two Day Review Course • July 15th and 16th 2016 8:00am – 5:00pm each day

Presenter: Jane Clark, PhD, RN, AOCN, GNP-C Place: Mayo Clinic Florida, Kinne Auditorium

Contact: Kathryn (Kathy) Whitson, Clinical Nurse Educator Hem/Onc/BMT 904-956-0387 Whitson.kathryn@mayo.edu

for more information and registration details.

2016 ASH Meeting on Hematologic Malignancies

The next ASH Meeting on Hematologic Malignancies, the only meeting with the unique "How I Treat" format, will take place September 16-17, 2016, in Chicago. Hear top experts discuss the latest developments in clinical care for hematologic malignancies, get answers to your most challenging cases, earn CME and MOC credit, and network with speakers and fellow attendees. Abstracts submitted to this meeting will be eligible or submission to the 2016 ASH Annual Meeting. Visit the website for more information and for a list of program speakers, and check out this video-playlist to hear even more program details from the co-chairs, speakers, and previous attendees.

26th Annual Mayo Clinic Hematology/Oncology Reviews



July 27-30, 2016 - Ritz-Carlton - Amelia Island, FL

Gerardo Colon-Otero, M.D. invites you to attend the 26th Annual Mayo Clinic Hematology/Oncology Reviews. This course is a comprehensive review of

hematology/oncology that focuses on the clinical application of new research developments over the preceding year. Didactic presentations will be case-based. Attendees will leave with

up-to-date, practical information which will have immediate clinical application. The most important clinical management questions in hematology/oncology will also be addressed in highly interactive sessions.

Save the Date: COA 2017 in Washington, DC

Save the date: #COA2017 will be in Washington, DC April 27-28, 2017. Join more than 1,000 physicians, patient advocates, practice administrators, nurses, industry representatives, and more for networking and learning in the nation's capital! Click here to download a calendar reminder for #COA2017.

FLASCO MEETINGS:

May 21, 2016 Florida Pancreas Cancer Coalition Summit (FLASCO Co-Sponsor) Orlando, FL

June 18-19, 2016 Florida Hospital Cancer Institute Best of ASCO (FLASCO Co-Sponsor), Hyatt Regency

Grand Cypress – Orlando, FL

July 8-10, 2016 Memorial Cancer Institute Best of ASCO (FLASCO Co-Sponsor), JW Marriott Marquis

Miami, Miami, FL Click here to view event.

July 22-24, 2016 11th Annual New Orleans Summer Cancer Meeting, Roosevelt Hotel, New Orleans, LA

50% Discount to FLASCO Members (FLASCO Co-Sponsor)

November 3-5, 2016 FLASCO Fall Session, Marriott World Center, Orlando, FL

February 4, 2017 Puerto Rico Business of Oncology, San Juan Resort and Stellaris Casino, San Juan, PR

March 29 - April 1, 2017 FLASCO Spring Session & Business of Oncology, Gaylord Palms, Kissimmee, FL

October 20-October 21, 2017 FLASCO Fall Session, Renaissance Orlando at Sea World

NATIONAL MEETINGS:

June 3-7, 2016 ASCO Annual Meeting, McCormick Place, Chicago Illinois

March 23 – 25, 2017 NCCN Annual Conference: Advancing the Standard of Cancer Care™ Rosen Shingle

Creek, Orlando, FL

September 16-17, 2016 ASH Meeting on Hematologic Malignancies, Fairmont Chicago, Millennium Park,

Chicago, IL

September 25 - 28, 2016 ASTRO Annual Meeting, Boston Convention and Exhibition Center, Boston, MA

December 3-6, 2016 ASH Annual Meeting, San Diego, CA **April 27-28, 2017** COA Annual Meeting, Washington, DC

LOCAL AND REGIONAL MEETINGS:

July 15-16, 2016 Oncology Nursing Certification Review Course, Mayo Clinic Florida, Jacksonville, FL 26th Annual Mayo Clinic Hematology/Oncology Reviews 2016, Amelia Island, Florida

August 25-27, 2016 7th Annual Latin American Conference on Lung Cancer, Panama City, Panama

Please visit the **FLASCO** website to view information on other events and meetings taking place in Florida.



FLASCO Proudly Recognizes the

2016 FLASCO CORPORATE MEMBERS

(**January 1 – December 31, 2016**)

DIAMOND	PLATINUM	GOLD	SILVER
Alexion	AbbVie	Clovis Oncology, Inc.	Helsinn
Amgen	AstraZeneca	Incyte	Ipsen BioPharmaceuticals, Inc
Astellas	Biodesix	Merrimack Pharmaceuticals	Spectrum Pharmaceuticals
Bayer Oncology	bioTheranostics, Inc.		Sysmex
Bristol-Myers Squibb	Boehringer Ingelheim		TESARO, Inc.
Celgene Corporation	Foundation Medicine		
Genentech BioOncology	Gilead Sciences, Inc.		
Heron Therapeutics Hospira Inc.	Infinity Pharmaceuticals, Inc Insys Therapeutics, Inc.		
Lilly Oncology	Medivation Field Solutions		
<u>Merck</u>	Myriad Genetics, Inc.		
<u>Pfizer</u>	NanoString Technologies		
Sandoz Inc.	Oncology Supply/ION Solutions		
Takeda Oncology	Paradigm Diagnostics		
TEVA Oncology	Pharmacyclics		
	Sanofi		
	Seattle Genetics		
	Taiho Oncology, Inc.		
	Walgreens		

FLASCO Contact Info:

Mailing Address:

Dorothy Green Phillips, Executive Director

10022 Water Works Lane Riverview, FL 33578 Office: 813.677.0246 Cell: 813.294.2620

Fax: 813.294.2620

Dorothy Phillips:Dorothy.Green@Flasco.orgKatrina Williams:Assistant@Flasco.orgJulie Newberry:Assistant3@Flasco.orgMary Lou von der Lancken:Assistant4@flasco.org

To unsubscribe from this or other FLASCO communications, please send unsubscribe to dorothy.green@flasco.org .